PDCD1 Recombinant Proteins 

PDCD1, commonly known as PD-1 (Programmed Cell Death Protein 1), is an immune checkpoint receptor expressed on T cells, B cells, and myeloid cells. It plays a pivotal role in regulating immune responses by interacting with its ligands, PD-L1 and PD-L2. Dysregulation of PD-1 signaling is implicated in immune exhaustion, particularly in cancer and chronic infections. 

Content on PDCD1 Recombinant Proteins

PDCD1 recombinant proteins are typically produced using mammalian or bacterial expression systems, ensuring high-quality production with preserved functionality. These proteins are designed to meet the rigorous demands of research and therapeutic development. Key features include:

• Structure: Often available as extracellular domains or fusion proteins (e.g., Fc-tagged for enhanced stability and detection).
• Purity: High purity levels, generally >95%, verified by SDS-PAGE and HPLC.
• Bioactivity: Retains ligand-binding activity with PD-L1/PD-L2 to mimic native interactions.

Application of PDCD1 Recombinant Proteins

• Immunotherapy Research:
  • Evaluates PD-1 interactions with PD-L1 and PD-L2 in the tumor microenvironment.
  • Used to study immune checkpoint blockade mechanisms.
• Antibody Development:
  • Supports the generation of monoclonal antibodies targeting PD-1 for therapeutic and diagnostic purposes.
• Functional Assays:
  • Applied in in vitro binding assays to study PD-1/PD-L1 interactions.
  • Utilized in cell-based assays to investigate T-cell exhaustion and reactivation.
• Drug Screening:
  • Facilitates the screening of PD-1/PD-L1 inhibitors and other immune checkpoint modulators.

PDCD1 recombinant proteins are essential tools in advancing our understanding of immune regulation and therapeutic strategies targeting immune checkpoint pathways. Their precise design and functionality make them invaluable in cancer immunotherapy research, drug development, and antibody generation efforts.